Soleno's first wave of rare dis­ease drug sales beats ex­pec­ta­tions

The first full quar­ter sales for Soleno Ther­a­peu­tics’ rare dis­ease drug Vykat XR are in, and they have ex­ceed­ed in­vestor fore­casts.

Soleno said Thurs­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.